share_log

Blonder Tongue Laboratories (NYSE:BDR) Receives New Coverage from Analysts at StockNews.com

kopsource ·  Jul 20, 2022 01:21

StockNews.com began coverage on shares of Blonder Tongue Laboratories (NYSE:BDR – Get Rating) in a research report report published on Saturday. The brokerage issued a hold rating on the stock.

Blonder Tongue Laboratories Stock Performance

Blonder Tongue Laboratories has a 52-week low of $0.28 and a 52-week high of $1.91. The firm has a market cap of $4.13 million, a PE ratio of -4.43 and a beta of 0.55. The business has a fifty day moving average price of $0.36. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.11 and a quick ratio of 0.38.

Get Blonder Tongue Laboratories alerts:

Blonder Tongue Laboratories (NYSE:BDR – Get Rating) last announced its quarterly earnings results on Friday, May 6th. The company reported ($0.09) earnings per share for the quarter. Blonder Tongue Laboratories had a negative net margin of 4.14% and a negative return on equity of 18.69%. The firm had revenue of $3.34 million during the quarter.

Blonder Tongue Laboratories Company Profile

(Get Rating)

Blonder Tongue Laboratories, Inc, a technology-development and manufacturing company, provides television (TV) signal encoding, transcoding, digital transport, and broadband product solutions in the United States. It offers encoders/transcoders, such as 4K/ultra-high definition, high definition and standard definition, MPEG-2, MPEG-4/H.264, and HEVC/H.265 capable encoders and transcoders; and QPSK and 8PSK, and QAM transcoders.

Featured Stories

  • Get a free copy of the StockNews.com research report on Blonder Tongue Laboratories (BDR)
  • Ford Races Higher: Has The Stock Finally Bottomed?
  • A Dose of AbbVie Stock Can Help Your Bear Market Portfolio
  • PayPal Stock is Attempting to Put in the Floor
  • These Consumer Stocks Will Thrive And Here's Why
  • High-Yield Dividend Hasbro May Have Hit Bottom

Receive News & Ratings for Blonder Tongue Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blonder Tongue Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment